Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 6894068
Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
expired -
US 6890917
Geldanamycin derivative and method of treating cancer using same
expired -
US 6887485
Nitric oxide-releasing metallic medical devices
expired -
US 6887466
Methods for selectively stimulating proliferation of T cells
expired -
US 6884413
Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (GCS)
expired -
US 6884414
Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
expired -
US 6884871
Isolation and use of tissue growth-inducing Frzb protein
expired -
US 6881718
Disulfide conjugated cell toxins and methods of making and using them
expired -
US 6881412
Modified live Flavobacterium columnare against columnaris disease in fish
expired -
US 6875433
Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
expired -
US 6872398
Conjugate vaccine against gram-negative bacterial infections
expired -
US 6871477
Method of manufacturing transdermal patches
expired -
US 6869602
Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells
expired -
US 6869787
Ricin vaccine and methods of making and using thereof
expired -
US 6869604
Recombinant anti-tumor RNAse
expired -
US 6869924
Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
expired -
US 6869925
Inhibition of retrovirus infection
expired -
US 6863885
Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
expired -
US 6861415
21-substituted progesterone derivatives as new antiprogestational agents
expired -
US 6858712
Cloning and expression of HTLV-III DNA
expired -
US 6858211
Vaccines against Escherichia coli O157 infection
expired -
US 6855323
Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A
expired -
US 6855322
Isolation and purification of P. falciparum merozoite protein-142 vaccine
expired -
US 6855331
Sustained release hydrophobic bioactive PLGA microspheres
expired -
US 6855314
AAV5 vector for transducing brain cells and lung cells
expired -
US 6852324
Immunization for ebola virus infection
expired -
US 6852842
Methods for functional kidney imaging using small dendrimer contrast agents
expired -
US 6852686
Methods for ameliorating icthyosiform skin diseases
expired -
US 6849417
Mammalian selenoprotein differentially expressed in tumor cells
expired -
US 6846911
Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 Ξ± subunit
expired -
US 6844190
St-B17 serotonin receptor
expired -
US 6844010
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
expired -
US 6838237
Antigenically reactive regions of the hepatitis a virus polyprotein
expired -
US 6838090
Water-insoluble drug delivery system
expired -
US 6833128
Method for monitoring local reaction associated with injections
expired -
US 6833132
Method of stimulating epithelial cells using keratinocyte growth factor (KGF) and method of inhibiting KGF activity
expired -
US 6830893
T20/DP178 is an activator of human phagocyte formyl peptide receptors
expired -
US 6828416
Recombinant multivalent malarial vaccine against Plasmodium falciparum
expired -
US 6828309
Use of pentosan polysulfate to treat certain conditions of the prostate
expired -
US 6825323
Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
expired -
US 6821511
Methods of using adeno-associated virus rep protein
expired -
US 6818749
Variants of humanized anti carcinoma monoclonal antibody cc49
expired -
US 6815425
Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
expired -
US 6815173
Method for detecting syphilis using synthetic antigents
expired -
US 6812246
Aminoflavone compounds, compositions, and methods of use thereof
expired -
US 6811782
Peptide composition as immunogen for the treatment of allergy
expired -
US 6808877
Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection
expired -
US 6809184
Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
expired
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory